Literature DB >> 34155379

The multiple sclerosis prodrome.

Naila Makhani1, Helen Tremlett2.   

Abstract

A prodrome is an early set of signs, symptoms or other findings that occur before the onset of typical symptoms of a disease. Prodromal phases are well recognized in several neurological and inflammatory diseases, but the possibility of a prodrome in multiple sclerosis (MS) has received relatively little attention until the past few years. In this Perspective, we summarize what is currently known about the MS prodrome, including its possible duration, clinical features and potential biomarkers. We also consider what insights and lessons can be learned from knowledge of and research into the prodromal phases of other diseases. A better understanding of the MS prodrome could have profound clinical implications as it could enable earlier recognition of MS and earlier initiation of treatments that reduce relapse rates and long-term disability. Knowledge of the MS prodrome could also affect research into the causes of MS, and putative risk factors must be re-evaluated in light of the MS prodrome. We conclude by outlining the major knowledge gaps and propose future initiatives.
© 2021. Springer Nature Limited.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34155379      PMCID: PMC8324569          DOI: 10.1038/s41582-021-00519-3

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN: 1759-4758            Impact factor:   42.937


  78 in total

1.  Fatigue, sleep disorders, anaemia and pain in the multiple sclerosis prodrome.

Authors:  Fardowsa LA Yusuf; José Ma Wijnands; Elaine Kingwell; Feng Zhu; Charity Evans; John D Fisk; Yinshan Zhao; Jason M Sutherland; David M Patrick; Ruth Ann Marrie; Helen Tremlett
Journal:  Mult Scler       Date:  2020-04-06       Impact factor: 6.312

2.  Cognitive function in radiologically isolated syndrome.

Authors:  Christine Lebrun; Frederic Blanc; David Brassat; Hélène Zephir; Jerome de Seze
Journal:  Mult Scler       Date:  2010-07-07       Impact factor: 6.312

3.  Preclinical disease activity in multiple sclerosis: A prospective study of cognitive performance prior to first symptom.

Authors:  Marianna Cortese; Trond Riise; Kjetil Bjørnevik; Alok Bhan; Elisabeth Farbu; Nina Grytten; Ineke Hogenesch; Rune Midgard; Cecilia Smith Simonsen; Wenche Telstad; Alberto Ascherio; Kjell-Morten Myhr
Journal:  Ann Neurol       Date:  2016-10       Impact factor: 10.422

4.  Contribution of the symptomatic lesion in establishing MS diagnosis and prognosis.

Authors:  Mar Tintore; Susana Otero-Romero; Jordi Río; Georgina Arrambide; Berta Pujal; Carmen Tur; Ingrid Galán; Manuel Comabella; Carlos Nos; María Jesús Arévalo; Angela Vidal-Jordana; Joaquin Castilló; Breogán Rodríguez-Acevedo; Luciana Midaglia; Raquel Mitjana; Cristina Auger; Jaume Sastre-Garriga; Àlex Rovira; Xavier Montalban
Journal:  Neurology       Date:  2016-08-26       Impact factor: 9.910

5.  Course and prognosis in early-onset MS: comparison with adult-onset forms.

Authors:  I L Simone; D Carrara; C Tortorella; M Liguori; V Lepore; F Pellegrini; A Bellacosa; A Ceccarelli; I Pavone; P Livrea
Journal:  Neurology       Date:  2002-12-24       Impact factor: 9.910

6.  A systematic review of morbidities suggestive of the multiple sclerosis prodrome.

Authors:  Fardowsa L A Yusuf; Bryan C Ng; José M A Wijnands; Elaine Kingwell; Ruth Ann Marrie; Helen Tremlett
Journal:  Expert Rev Neurother       Date:  2020-05-18       Impact factor: 4.618

Review 7.  Factors associated with onset, relapses or progression in multiple sclerosis: A systematic review.

Authors:  Kyla A McKay; Shayesteh Jahanfar; Tom Duggan; Stacey Tkachuk; Helen Tremlett
Journal:  Neurotoxicology       Date:  2016-04-01       Impact factor: 4.294

8.  Mounting evidence for a multiple sclerosis prodrome.

Authors:  Ruth Ann Marrie
Journal:  Nat Rev Neurol       Date:  2019-12       Impact factor: 42.937

9.  Oligoclonal bands increase the specificity of MRI criteria to predict multiple sclerosis in children with radiologically isolated syndrome.

Authors:  Naila Makhani; Christine Lebrun; Aksel Siva; Sona Narula; Evangeline Wassmer; David Brassat; J Nicholas Brenton; Philippe Cabre; Clarisse Carra Dallière; Jérôme de Seze; Francoise Durand Dubief; Matilde Inglese; Megan Langille; Guillaume Mathey; Rinze F Neuteboom; Jean Pelletier; Daniela Pohl; Daniel S Reich; Juan Ignacio Rojas; Veronika Shabanova; Eugene D Shapiro; Robert T Stone; Silvia Tenembaum; Mar Tintoré; Ugur Uygunoglu; Wendy Vargas; Sunita Venkateswaren; Patrick Vermersch; Orhun Kantarci; Darin T Okuda; Daniel Pelletier
Journal:  Mult Scler J Exp Transl Clin       Date:  2019-03-20

10.  The earlier, the better or the worse? Towards accurate management of patients with arthralgia at risk for RA.

Authors:  Annette van der Helm-van Mil; Robert B M Landewé
Journal:  Ann Rheum Dis       Date:  2020-01-08       Impact factor: 19.103

View more
  10 in total

1.  The multiple sclerosis prodrome is just unspecific symptoms in radiologically isolated syndrome patients - Commentary.

Authors:  Naila Makhani
Journal:  Mult Scler       Date:  2021-09-08       Impact factor: 6.312

Review 2.  From the prodromal stage of multiple sclerosis to disease prevention.

Authors:  Ruth Ann Marrie; Mark Allegretta; Lisa F Barcellos; Bruce Bebo; Peter A Calabresi; Jorge Correale; Benjamin Davis; Philip L De Jager; Christiane Gasperi; Carla Greenbaum; Anne Helme; Bernhard Hemmer; Pamela Kanellis; Walter Kostich; Douglas Landsman; Christine Lebrun-Frenay; Naila Makhani; Kassandra L Munger; Darin T Okuda; Daniel Ontaneda; Ronald B Postuma; Jacqueline A Quandt; Sharon Roman; Shiv Saidha; Maria Pia Sormani; Jon Strum; Pamela Valentine; Clare Walton; Kathleen M Zackowski; Yinshan Zhao; Helen Tremlett
Journal:  Nat Rev Neurol       Date:  2022-07-15       Impact factor: 44.711

Review 3.  Preclinical Autoimmune Disease: a Comparison of Rheumatoid Arthritis, Systemic Lupus Erythematosus, Multiple Sclerosis and Type 1 Diabetes.

Authors:  Giulia Frazzei; Ronald F van Vollenhoven; Brigit A de Jong; Sarah E Siegelaar; Dirkjan van Schaardenburg
Journal:  Front Immunol       Date:  2022-06-30       Impact factor: 8.786

Review 4.  Biological Markers in Early Multiple Sclerosis: the Paved Way for Radiologically Isolated Syndrome.

Authors:  Manon Rival; Manon Galoppin; Eric Thouvenot
Journal:  Front Immunol       Date:  2022-04-27       Impact factor: 8.786

5.  The Multiple Sclerosis Prodrome: Evidence to Action.

Authors:  Helen Tremlett; Kassandra L Munger; Naila Makhani
Journal:  Front Neurol       Date:  2022-01-31       Impact factor: 4.086

Review 6.  Secondary Prevention in Radiologically Isolated Syndromes and Prodromal Stages of Multiple Sclerosis.

Authors:  Maria Pia Amato; Nicola De Stefano; Matilde Inglese; Emanuele Morena; Giovanni Ristori; Marco Salvetti; Maria Trojano
Journal:  Front Neurol       Date:  2022-03-14       Impact factor: 4.003

7.  Axonal injury in asymptomatic individuals preceding onset of multiple sclerosis.

Authors:  Daniel Jons; Henrik Zetterberg; Martin Biström; Lucia Alonso-Magdalena; Martin Gunnarsson; Magnus Vrethem; Kaj Blennow; Staffan Nilsson; Peter Sundström; Oluf Andersen
Journal:  Ann Clin Transl Neurol       Date:  2022-05-03       Impact factor: 5.430

8.  Free vitamin D3 index and vitamin D-binding protein in multiple sclerosis: A presymptomatic case-control study.

Authors:  Viktor Grut; Martin Biström; Jonatan Salzer; Pernilla Stridh; Anna Lindam; Lucia Alonso-Magdalena; Oluf Andersen; Daniel Jons; Martin Gunnarsson; Magnus Vrethem; Johan Hultdin; Peter Sundström
Journal:  Eur J Neurol       Date:  2022-06-04       Impact factor: 6.288

9.  Phenotypical changes of satellite glial cells in a murine model of GM1 -gangliosidosis.

Authors:  Bei Huang; Isabel Zdora; Nicole de Buhr; Deborah Eikelberg; Wolfgang Baumgärtner; Eva Leitzen
Journal:  J Cell Mol Med       Date:  2021-12-07       Impact factor: 5.310

Review 10.  PET imaging of reactive astrocytes in neurological disorders.

Authors:  Yu Liu; Han Jiang; Xiyi Qin; Mei Tian; Hong Zhang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-12-07       Impact factor: 9.236

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.